Obermatt
See Similar Stocks →

Geron

NSQ:GERN · US3741631036
BiotechnologySmall

360

22
Profit price74
Cash yield1
Price/Sales89
EV / Gross Profit70
Price/Book49
Return on Capital70
Cash Return on Capital62
Return on Equity67
EBIT Margin44
Gross Profitability60
Accruals48
Owner Earnings Margin53
Sales growth53
Profit growth92
Reinvestment97
Price momentum10
Debt load23
Refinancing100
Debt Payback1
Liquidity91
Analyst ratings9
Opinion Changes50
Price Target Upside83
Market mood95
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Geron doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded1990
Employees238
Websitegeron.com
ISINUS3741631036
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesHematologyOncologyBiopharmaBiotechnologyHealth DiagnosticsPharmaceutical

Description

Geron Corporation operates as a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. The company’s first-in-class telomerase inhibitor, RYTELO (imetelstat), harnesses Nobel Prize winning science i…

Analysis

Middle-of-the-road

Geron Corporation sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

Flags to be aware of: Some accounting patterns deserve a closer look. Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
94
2026

All-time high

94

Jun 2026

All-time low

85

Mar 2026

Average rank

90

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
89
—
—
—
Price/Earnings
100
—
—
—
Price/Book
49
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
94
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Geron with its peers
Arcellx
NSQ:ACLX
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Prelude Therapeutics
NSQ:PRLD
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Scholar Rock
NSQ:SRRK
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Day One Biopharmaceuticals
NSQ:DAWN
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Adaptive Biotechnologies
NSQ:ADPT
20
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →